NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy

RecruitingN/A

Sponsor: Nationwide Children's Hospital

Conditions: LAMA2-MD \(Merosin Deficient Congenital Muscular Dystrophy, MDC1A\)

Countries: United States

The goal of this observational study is to understand how young children with LAMA2-related dystrophy move and change over time. We will also learn about how this condition impacts other body systems. Participants will undergo: * Neuromuscular assessments * Blood collections * Swallowing and breathing assessments * Questionnaires

Eligibility overview

Sex: ALL

Age: — to 5 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Signed informed consent by the subject, parent(s) or legally authorized representative (LAR) and/or assent by the subject (when applicable).
* Subject must be aged birth to less than 5.0 years of age at time of consent.
* A confirmed diagnosis of LAMA2-RD confirmed via:

  a: Two pathogenic variants in the LAMA2 gene (via a CLIA-approved laboratory) or: b. muscle biopsy with absence of merosin (laminin-211) and at least one pathogenic variant in the LAMA2 gene
* Absence of another confirmed genetic disease.
* Willingness to maintain current exercise and/or physical therapy regimen for the duration of the clinical study.
* Willingness to comply with the study protocol, including but not limited to, all study procedures and visits.

Exclusion Criteria:

* Acute medical illness or hospitalization within 30 days prior to informed consent.
* Participation in a previous trial of any investigational agent for LAMA2-RD within 1 month prior to informed consent, or use of any other investigational therapy (including off-label use of Losartan) within 30 days prior to informed consent, or participation in other clinical studies, within 30 days (or 3 half-lives, whichever is longer) prior to informed consent, which in the opinion of the PI, may potentially confound results from this study.
* Other significant medical condition, which in the opinion of the site Principal Investigator may confound interpretation of the clinical course of LAMA2- RD.

Locations (14)

Los Angeles, California, United States
Stanford, California, United States
Chicago, Illinois, United States
Iowa City, Iowa, United States
Bethesda, Maryland, United States
Boston, Massachusetts, United States
Saint Paul, Minnesota, United States
St Louis, Missouri, United States
Rochester, New York, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Pittsburgh, Pennsylvania, United States
Dallas, Texas, United States
Salt Lake City, Utah, United States